Patents by Inventor James A. Fornwald

James A. Fornwald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080318835
    Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions.
    Type: Application
    Filed: February 29, 2008
    Publication date: December 25, 2008
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett, Gregg A. Hastings
  • Publication number: 20080312146
    Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.
    Type: Application
    Filed: May 21, 2007
    Publication date: December 18, 2008
    Applicants: Human Genome Sciences, Inc., Beth Israel Deaconess Medical Center, SmithKline Beecham Corp.
    Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
  • Patent number: 7220557
    Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: May 22, 2007
    Assignees: Human Genome Sciences, Inc., Beth Israel-Deaconess Medical Center, SmithKline Beecham Corporation
    Inventors: Gregg A. Hastings, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
  • Publication number: 20040175794
    Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.
    Type: Application
    Filed: January 15, 2004
    Publication date: September 9, 2004
    Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.
    Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathon A. Terrett, Gregg A. Hastings
  • Publication number: 20040002449
    Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.
    Type: Application
    Filed: November 21, 2001
    Publication date: January 1, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
  • Publication number: 20030166065
    Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retinopathy), restenosis, Alzheimer's disease and tissue remodeling, among others, and diagnostic assays for such conditions.
    Type: Application
    Filed: April 4, 2002
    Publication date: September 4, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathon A. Terrett, Gregg A. Hastings
  • Patent number: 5498529
    Abstract: This invention relates to a process for producing a heterologous polypeptide in Streptomyces which involves transforming a Streptomyces organism with a recombinant DNA molecule comprising an LEP-10 of LTl sequence selected from the group consisting of a sequence encoding a gene expression unit, a promoter sequence or an export control encoding sequence each operatively linked to a heterologous coding sequence and then culturing the transformed Streptomyces such that the heterologous polypeptide is expressed.
    Type: Grant
    Filed: December 3, 1993
    Date of Patent: March 12, 1996
    Assignee: SmithKline Beckman Corporation
    Inventors: Thomas R. Berka, James A. Fornwald, Joselina G. Gorniak, Martin Rosenberg, James E. Strickler, Dean P. Taylor
  • Patent number: 5435730
    Abstract: A recombinant DNA molecule comprising the Streptomyces gal operon galK gene; galE gene; galT gene; P1 promoter; P2 promoter; P2 promoter expression unit; P1 promoter regulated region; or the entire Streptomyces gal operon.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: July 25, 1995
    Inventors: Craig W. Adams, Mary E. Brawner, James A. Fornwald, Francis J. Schmidt
  • Patent number: 5279939
    Abstract: This invention relates to novel protein protease inhibitors as well as DNAs encoding same and vectors and transformed host cells useful for the recombinant production of the inhibitors.
    Type: Grant
    Filed: June 3, 1992
    Date of Patent: January 18, 1994
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas R. Berka, James A. Fornwald, Joselina G. Gorniak, Martin Rosenberg, James E. Strickler, Dean P. Taylor
  • Patent number: 5242809
    Abstract: A recombinant DNA molecule comprising the Streptomyces gal operon galK gene; galE gene; galT gene; P1 promoter, P2 promoter, P2 promoter expression unit; P1 promoter regulated region; or the entire Streptomyces gal operon.
    Type: Grant
    Filed: October 27, 1992
    Date of Patent: September 7, 1993
    Assignee: SmithKline Beecham Corporation
    Inventors: Craig W. Adams, Mary E. Brawner, James A. Fornwald, Francis J. Schmidt